Next Generation Antibody Therapeutics Market

Next Generation Antibody Therapeutics Market: Overview

As the name suggests, next-generation antibody therapeutics is characteristic of advanced antibody therapeutics. This is because of their enhanced efficacy, greater safety, and targeted treatment properties. Currently, most of the next-generation antibody therapeutics are restricted to clinical environments due to lack of approval from the FDA and other regulatory bodies. However in a time span of five years most of these next generation antibody therapeutics are likely to receive required approval. This can be attributed to the ongoing research and advancements in monoclonal antibody technologies. It is expected to offer a significant boost to the next-generation antibody therapeutics market by the end of the forecast period

Next Generation Antibody Therapeutics Market: Notable Developments

Some of the recent developments that may favor next generation antibody therapeutics market are:

• Zumutor Biologics  have developed Afucosylated AntiHer2 Antibody. The company belives that its offers 15 folds improvement in antibody-dependent cellular cytotoxicity as compared to trastuzumab drug. In addition to this, the company has also developed unique antibody display libraries for discovery and development of new antibody drug molecules.

• Seattle Genetics, started a clinical trial of brentuximab vedotin, a next generation antibody therapeutics. This could help in the efficient treatment of systemic lupus erythematous. At present there is not reliable treatment for the disease.  

• Netherlands Synthon is investigating SYD985, a next generation antibody drug. The company believes that this drug will facilitate treatment options for breast cancer and can including triple negative breast cancer. 

Some of the prominent players in Pfizer, Roche, Bristol-Myers, Squibb, Amgen, AstraZeneca, Biogen, Seattle Genetics and ImmunoGen

Next Generation Antibody Therapeutics Market: Key Trend

The global next generation antibody therapeutics market is likely to grow at a significant pace during the forecast period. This is mainly because of efficacy of next-generation antibody therapeutics for chronic diseases such as cancer and autoimmune diseases. In general, antibody therapeutics have been undergoing consistent scientific advancements to boost their efficacy.

The use of advanced technology in antibody therapeutics, such as antibody-drug conjugate (ADC), glycoengineered antibody, and specific antibodies (BsAbs) has resulted in the development of next generation antibody therapeutics. The growing prevalence of chronic diseases and rare disorders are expected to offer lucrative avenue for the growth of the next generation antibody therapeutics market.

However, limited awareness and high cost of the treatment using next generation antibody therapeutics is expected to impede growth of the next generation antibody therapeutics market. The next generation antibody therapeutics market is in its initial phase. Currently, only a handful of next-generation antibody therapeutics are used in clinics and hospital environments. The success outcomes of these drugs is expected to offer a significant boost to this market.

Next Generation Antibody Therapeutics Market: Regional Outlook

Geographically, North America is expected to dominate the next generation antibody therapeutics market in the forecast period. This is due to high investment on research and development of the next generation antibody drugs by governments in the region. Moreover, surge in the geriatric population in the region is another factor likely to boost the market in the region. Apart from this,  increasing prevalence of chronic diseases in the region is expected to fuel the next-generation antibody therapeutics market in North America.